|
James Barry, PhD, is Vice President, Corporate Research and Advanced Technology Development at Boston Scientific. He is responsible for the Company’s Corporate Research & Development Function, which includes the development of drug/device combination technologies including implant and catheter-based delivery systems. Dr. Barry joined Boston Scientific in 1992. Under his leadership, Boston Scientific developed the TAXUS coronary stent, a paclitaxel-eluting stent technology that has lead to significant reduction in the rate of restenosis in angioplasty patients. Prior to joining Boston Scientific, Dr. Barry worked at the Howmedica Division of Pfizer Hospital Products Group as a Principal Research Scientist. Prior to that position he worked with Kontron Instruments, Inc. Dr. Barry is well published in the field of Controlled Release, Biomaterials and Drug Device Combinations. Dr. Barry holds a PhD in Biochemistry from the University of Massachusetts and a BA degree in chemistry from Saint Anselm College. | 